![newly identified pet biomarker predicts success of immune checkpoint blockade therapy](https://utterbuzz.com/wp-content/uploads/2024/05/newly-identified-pet-biomarker-predicts-success-of-immune-checkpoint-blockade-therapy-640x512.jpg)
The protein galectin-1 (Gal-1) has been identified as a new PET imaging biomarker for immune checkpoint blockade (ICB) therapy, allowing physicians to predict the tumor responses before beginning treatment. Information garnered from Gal-1 PET imaging could also be used to facilitate patient stratification and optimize immunotherapy, enabling targeted interventions and improving patient outcomes.